Hideharu Kimura

Hideharu Kimura

Auto-generated profile, based on publicly available information

Hideharu Kimura

Department of Respiratory Medicine, Kanazawa University Hospital

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Clinical Lung Cancer
Verified
Journal Article
Closed access
HMHiroki Matsuoka
Hiroki Matsuoka
HKHideharu Kimura
Hideharu Kimura
HKHayato Koba
Hayato Koba
YTYuichi Tambo
Yuichi Tambo
NONoriyuki Ohkura
Noriyuki Ohkura
KKKazuo Kasahara
Kazuo Kasahara

1 March 2013 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
DTDaisuke Tamura
Daisuke Tamura
TATokuzo Arao
Tokuzo Arao
TNTomoyuki Nagai
Tomoyuki Nagai
HKHiroyasu Kaneda
Hiroyasu Kaneda
KAKeiichi Aomatsu
Keiichi Aomatsu
KNKazuto Nishio
Kazuto Nishio
Transcription factor Slug/SNAI2 (snail homolog 2) plays a key role in the induction of the epithelial mesenchymal transition in cancer cells; however, whether the overexpression of Slug mediates the malignant phenotype and alters drug sensitivity in lung cancer cells remains largely unclear. We investigated Slug focusing on its biological function and involvement in drug sensitivity in lung cancer cells. Stable Slug transfectants showed typical morphological changes compared with control cells. Slug overexpression did not change the cellular proliferations; however, migration activity and anchorage‐independent growth activity with an antiapoptotic effect were increased. Interestingly, stable Slug overexpression increased drug sensitivity to tubulin‐binding agents including vinorelbine, vincristine, and paclitaxel (5.8‐ to 8.9‐fold increase) in several lung cancer cell lines but did not increase sensitivity to agents other than tubulin‐binding agents. Real‐time RT‐PCR (polymerase chain reaction) and western blotting revealed that Slug overexpression downregulated the expression of βIII and βIVa‐tubulin, which is considered to be a major factor determining sensitivity to tubulin‐binding agents. A luciferase reporter assay confirmed that Slug suppressed the promoter activity of βIVa‐tubulin at a transcriptional level. Slug overexpression enhanced tumor growth, whereas Slug overexpression increased drug sensitivity to vinorelbine with the downregulation of βIII and βIV‐tubulin in vivo. Immunohistochemistry of Slug with clinical lung cancer samples showed that Slug overexpression tended to be involved in response to tubulin‐binding agents. In conclusion, our data indicate that Slug mediates an aggressive phenotype including enhanced migration activity, anoikis suppression, and tumor growth, but increases sensitivity to tubulin‐binding agents via the downregulation of βIII and βIVa‐tubulin in lung cancer cells.

21 November 2019 in Cancer Communications
Verified
Journal Article
Open access
PDF file
HKHideharu Kimura
Hideharu Kimura
TATomoyuki Araya
Tomoyuki Araya
TYTaro Yoneda
Taro Yoneda
HSHiroki Shirasaki
Hiroki Shirasaki
KKKoji Kurokawa
Koji Kurokawa
KKKazuo Kasahara
Kazuo Kasahara

1 October 2016 in Allergology International
Verified
Journal Article
Open access
SWSatoshi Watanabe
Satoshi Watanabe
HKHideharu Kimura
Hideharu Kimura
HTHazuki Takato
Hazuki Takato
YWYuko Waseda
Yuko Waseda
JHJohsuke Hara
Johsuke Hara
KKKazuo Kasahara
Kazuo Kasahara

28 October 2011 in Cancer Science
Verified
Journal Article
Open access
PDF file
KFKazuyuki Furuta
Kazuyuki Furuta
TATokuzo Arao
Tokuzo Arao
KSKazuko Sakai
Kazuko Sakai
HKHideharu Kimura
Hideharu Kimura
TNTomoyuki Nagai
Tomoyuki Nagai
KNKazuto Nishio
Kazuto Nishio
Whole genome‐scale integrated analyses of exon array and array‐comparative genomic hybridization are expected to enable the identification of unknown genetic features of cancer cells. Here, we evaluated this approach in 22 gastric and colorectal cancer cell lines, focusing on protein kinase genes and genes belonging to the cadherin–catenin family. Regarding alternative splicing patterns, several cancer cell lines predominantly expressed isoform 1 of protein kinase A catalytic subunit beta (PRKACB). Paired gastric cancer specimens demonstrated that isoform 1 of PRKACB was a novel cancer‐related variant transcript in gastric cancers. In addition, the exon array analysis clearly identified exon 3 or exon 3–4 skipping in catenin beta 1, a short intron insertion with exon 9 skipping in CDH1, and a deletional transcript of CDH13. These abnormal transcripts were shown to have arisen from small genomic deletions. Meanwhile, an integrated analysis of 11 gastric cancer cell lines revealed that four cell lines amplified fibroblast growth factor receptor 2, with truncated forms observed in two of the cell lines. Gene amplification, and not the truncated form, was found to determine the sensitivity to a fibroblast growth factor receptor inhibitor, indicating that our cell line panel might be useful for cell‐based evaluations of specific inhibitors. Using an integrated analysis, we identified several abnormal transcripts and genomic alterations in gastric and colorectal cancer cells. Our approach might enable genetic changes to be identified more efficiently, and the present results warrant further investigation using clinical samples and integrated analyses. (Cancer Sci 2012; 103: 221–227)

1 December 2021 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
HKHayato Koba
Hayato Koba
HKHideharu Kimura
Hideharu Kimura
TYTaro Yoneda
Taro Yoneda
NONaohiko Ogawa
Naohiko Ogawa
KTKota Tanimura
Kota Tanimura
KKKazuo Kasahara
Kazuo Kasahara
Background: Molecular targeted therapy has been developed as an innovative treatment for metastatic cancer. Epidermal growth factor receptor (EGFR) mutation is one of the most important and frequent oncogenic drivers in non-small-cell lung cancer, and EGFR-tyrosine kinase inhibitors are indispensable drugs for mutation-positive patients. Currently, the acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is a problem, the mechanism of which has not been elucidated. The histological transformation from original adenocarcinoma to small-cell carcinoma is rare; however, it has been detected in many cases after EGFR-TKI treatment. This study aimed to evaluate mutational status in two different histological types and further elucidate the molecular pathogenesis. Methods: Three patients with EGFR-mutant lung cancer who underwent a histological transformation to small-cell carcinoma after growth factor receptor-TKI treatment were enrolled in this study. Two samples per patient were collected from histologically different lesions, and DNA samples were extracted from formalin-fixed, paraffin-embedded tumor tissues. The paired samples were subjected to next-generation sequencing of 160 cancer-related genes. Based on the sequencing results, the expression levels of related proteins were validated using reverse-transferase polymerase chain reaction and immunohistochemical staining. Results: The following five variants were common among the three cases: MTOR, JAK1, NOTCH2, CSF1R, and MAP2K2. The former four variants were additive to small-cell carcinoma, and the last variant was lost. Both TP53 and Rb1 alterations were detected in adenocarcinoma. Notch2 expression was negative in small-cell carcinoma in both reverse-transcriptase polymerase chain reaction analysis and immunohistochemical staining. ASCL1 expression increased after histological transformation detected using both methods in one case, only these samples were evaluable. Conclusions: Notch and ASCL1 signaling are the master regulators of neuroendocrine differentiation in small-cell lung carcinoma. Our results suggest that the Notch-ASCL1 axis may also play an essential role in the transformation of small-cell carcinoma under TP53 and RB1 inactivation.